Clinical Trial Update: Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating direct tumor microinjection and FDG-PET to test drug sensitivity in patients with relapsed or refractory non-Hodgkin lymphoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cutaneous T-cell Lymphoma
• Hodgkin Lymphoma
• Mycosis Fungoides
• Non-hodgkin Lymphoma

Snippet

Sponsor: Mayo Clinic | Conditions: Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Status: TERMINATED